To ensure compliance success in a changing regulatory landscape, laboratories must continually adapt. Learn how the compliant-ready Waters BioAccord LC-MS platform helps biopharma address the additional compliance challenges posed by the field’s complex analytical instruments.
During 2020, we collaborated with many of our customers to develop targeted liquid chromatography–mass spectrometry/mass spectrometry (LC-MS/MS) methods to detect SARS-CoV-2 (the virus that causes COVID-19) from biological samples. However, the combination of the biological specimen, the sample collection medium, the viral load threshold, and the need for a high throughput method gave rise to…
Oligonucleotides, or short strands of DNA or RNA, continue to increase in popularity. In addition to their essential role as primers and probes in the expanding clinical DNA testing and diagnostics market, they’re also seeing great success as new gene-based therapeutics that hold tremendous promise. With a string of recent drug approvals, including the first…
As scientific advances continue to carry researchers into new arenas, it is vital that technology evolves in tandem. At Waters, we understand that it is only by leveraging fit-for-purpose technologies that researchers are able to unleash their creativity and make pioneering scientific breakthroughs. Scientists working within the rapidly growing biopharmaceutical industry are no exception. With…
In this series, we review considerations for keeping your lab at the forefront of science. As you adjust to living and working in a pandemic and anticipate future global and geopolitical events, Waters remains dedicated to supporting your business and unlocking the potential of your science. Our holistic separations solutions and expert support help you…
Chances are that you or someone you know has been directly impacted by breast cancer. With 2,088,849 new cases and 626,679 deaths globally,1 it is the most frequently diagnosed cancer in women in most countries (154 of 185) and is the leading cause of cancer death in women in over 100 countries. Fortunately, significant strides…
Many years ago, I was hired by a biopharma company to develop analytical methods for therapeutic oligonucleotides. When a new colleague warned me about sample loss on LC columns I looked at him with skepticism. “Yes,” he insisted, “part of your DNA sample may be irreversibly bound to the column and you will never see…
In January of 2018, Waters kicked off its global Bioharmonization campaign with a blog post and video release, laying out a vision for how the Biopharmaceutical industry can achieve accelerated development and improved quality while enhancing productivity and lowering production costs. Central to this vision are “fit-for-purpose” analytical tools working together within a single compliance-ready…
After completing my undergraduate degree, I began work at the New England Newborn Screening Program (NENBS) in Jamaica Plain, Massachusetts. It wasn’t long before I realized the magnitude of the job I held in serving the public and my role in the life-saving tests that the program performed. The NENBS program consists of five testing…
What does “intelligence” mean in the context of biopharma analysis? Given the complex setting, much of the answer comes down to the task a user needs to complete, along with the question of who exactly that user is. In developing our BioAccord System, we wanted to expand the possibilities of high-resolution LC-MS analysis from characterization…
Newborn screening for inherited disorders has been heralded as one of the 10 greatest public health achievements of the first decade of the 21st century.1 The ability to pre-symptomatically identify newborn babies at risk of developing endocrine, hematologic, and metabolic disorders has dramatically improved or saved thousands of lives (and saved the healthcare system millions…
We’ve updated our UPLC systems to enable you to find faster, simpler, and better ways to do your work. Take a closer look at our new and improved ACQUITY UPLC PLUS Series.